Department of Imaging, Institut Gustave Roussy, Villejuif, France.
Department of Imaging, Institut Gustave Roussy, Villejuif, France.
Dig Liver Dis. 2017 Oct;49(10):1121-1127. doi: 10.1016/j.dld.2017.05.015. Epub 2017 Jun 28.
Accurate measurement of well-differentiated neuroendocrine tumours (NET) liver metastases is critical to determine tumour slope and to assess treatment efficacy. Our objectives were to determine which CT or MRI sequence is the most reproducible to measure NET liver metastases and to assess the percentage of variability of measurements. Intra and inter-observer variability were studied on triphasic abdominal CT or liver MRI in 22 and 32 NET patients respectively. Patients were treatment-naïve or under somatostatin analogues. A maximum of 5 liver target lesions per patient was defined and three radiologists measured them on each sequence. Reproducibility were analysed by calculating the relative variation (RV) as defined by RECIST criteria. We analysed 1656 target measurements for CT and 3384 for MRI. Intra-observers RV were better than inter-observers. T2 for MRI and portal-phase for CT were associated with the lowest measurement variability. The MRI sequence offering the best intra and inter-observer reproducibility is the T2W-sequence. MRI allows more reproducible measurement than CT (inter-observer RV <20% in 96.8% for MRI and 81% for CT). Our study demonstrates intermediate to high imaging reproducibility of liver metastases measurements in NET patients. Non-enhanced MRI should be preferred to triphasic-CT for follow-up, assessment of treatment and trials.
准确测量分化良好的神经内分泌肿瘤(NET)肝转移瘤对于确定肿瘤斜率和评估治疗效果至关重要。我们的目的是确定哪种 CT 或 MRI 序列最具可重复性,以测量 NET 肝转移瘤,并评估测量的可变性百分比。在 22 名和 32 名 NET 患者中分别对三相腹部 CT 或肝脏 MRI 进行了内部和观察者间的可重复性研究。患者均为初治或正在接受生长抑素类似物治疗。每位患者最多定义 5 个肝脏靶病变,每位观察者在每个序列上对其进行测量。通过根据 RECIST 标准计算相对变化(RV)来分析可重复性。我们分析了 CT 的 1656 个靶测量值和 MRI 的 3384 个靶测量值。内部观察者的 RV 优于外部观察者。MRI 的 T2 加权和 CT 的门静脉期与最低的测量可变性相关。提供最佳内部和外部观察者可重复性的 MRI 序列是 T2W 序列。MRI 允许更可重复的测量(MRI 的观察者间 RV<20%,CT 为 81%)。我们的研究表明,NET 患者肝转移瘤测量的影像学可重复性为中等至高。在随访、评估治疗和试验中,非增强型 MRI 应优先于三相 CT。